Table 1 Demographic and clinicopathological information for subjects involved in this study.
From: The ryanodine receptor mutational characteristics and its indication for cancer prognosis
Factors | Categories | Number of subjects |
|---|---|---|
Sex | Male | 5397 |
Female | 5603 | |
Age | < 40 | 868 |
40–49 | 1192 | |
50–59 | 2214 | |
60–69 | 2693 | |
70–79 | 1951 | |
≥ 80 | 685 | |
Not specified | 1397 | |
Smoking history* | 1 | 868 |
2 | 759 | |
3 | 661 | |
4 | 877 | |
5 | 61 | |
Not specified | 7774 | |
Cancer types | ACC | 98 |
BLCA | 573 | |
BRCA | 1054 | |
CESC | 297 | |
CHOL | 58 | |
COAD | 446 | |
DLBC | 37 | |
ESCA | 199 | |
GBM | 390 | |
HNSC | 541 | |
KICH | 73 | |
KIRC | 389 | |
KIRP | 338 | |
LAML | 134 | |
LGG | 520 | |
LIHC | 400 | |
LUAD | 603 | |
LUSC | 555 | |
MESO | 88 | |
OV | 438 | |
PAAD | 176 | |
PCPG | 209 | |
PRAD | 515 | |
READ | 146 | |
SARC | 278 | |
SKCM | 490 | |
STAD | 447 | |
TGCT | 133 | |
THCA | 518 | |
THYM | 133 | |
UCEC | 575 | |
UCS | 65 | |
UVM | 84 | |
Clinical stages | I | 2138 |
II | 2251 | |
III | 1763 | |
IV | 888 | |
Not specified | 3960 | |
RYR1 mutational status | WT | 10,018 |
Mutant | 982 | |
RYR2 mutational status | WT | 9508 |
Mutant | 1492 | |
RYR3 mutational status | WT | 9976 |
Mutant | 1024 |
